Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 471375, 6 pages
http://dx.doi.org/10.1155/2010/471375
Clinical Study

Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy

1Dattoli Cancer Center & Brachytherapy Research Institute, 2803 Fruitville Rd., Sarasota, FL 34237-5367, USA
2Department of Radiation Oncology and Pathology, University of Washington, Seattle, WA 98195-0001, USA
3Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108-1597, USA
4Group Health Cooperative, Seattle, WA 98124-1590, USA
5Research Division, Bostwick Laboratories, Richmond, VA 23050-4410, USA

Received 28 April 2010; Revised 1 July 2010; Accepted 1 July 2010

Academic Editor: Minesh P. Mehta

Copyright © 2010 Michael Dattoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [24 citations]

The following is the list of published articles that have cited the current article.

  • Karel A Hinnen, and Marco van Vulpen, “ Predictors in the outcome of 125 I brachytherapy as monotherapy for prostate cancer ,” Expert Review of Anticancer Therapy, vol. 11, no. 1, pp. 115–123, 2011. View at PublisherView at Google Scholar
  • James L. Mohler, Eric Mark Horwitz, Philip W. Kantoff, Michael Kuettel, Richard J. Lee, David Miller, Andrew J. Armstrong, Sandy Srinivas, Jonathan Tward, Przemyslaw Twardowski, Maria Ho, Robert R. Bahnson, James A. Eastham, Charles A. Enke, Celestia S. Higano, Mark H. Kawachi, Gary R. MacVicar, Arnold W. Malcolm, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Stan Rosenfeld, Seth A. Strope, Patrick C. Walsh, Dorothy A. Shead, Barry Boston, J. Erik Busby, Anthony Victor D'Amico, and Thomas Farrington, “Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 9, pp. 1081–1087, 2012. View at PublisherView at Google Scholar
  • Marisa A. Kollmeier, and Michael J. Zelefsky, “How to select the optimal therapy for early-stage prostate cancer,” Critical Reviews in Oncology/Hematology, vol. 83, no. 2, pp. 225–234, 2012. View at PublisherView at Google Scholar
  • Marisa A. Kollmeier, Xin Pei, Ece Algur, Yoshiya Yamada, Brett W. Cox, Gil’ad N. Cohen, Marco Zaider, and Michael J. Zelefsky, “A comparison of the impact of isotope (125I vs. 103Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer,” Brachytherapy, vol. 11, no. 4, pp. 271–276, 2012. View at PublisherView at Google Scholar
  • Patrick J. Bastian, Stephen A. Boorjian, Alberto Bossi, Alberto Briganti, Axel Heidenreich, Stephen J. Freedland, Francesco Montorsi, Mack Roach, Fritz Schroder, Hein van Poppel, Christian G. Stief, Andrew J. Stephenson, and Michael J. Zelefsky, “High-Risk Prostate Cancer: From Definition to Contemporary Management,” European Urology, vol. 61, no. 6, pp. 1096–1106, 2012. View at PublisherView at Google Scholar
  • Zachary S Zumsteg, and Michael J Zelefsky, “Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?,” The Lancet Oncology, vol. 13, no. 6, pp. e259–e269, 2012. View at PublisherView at Google Scholar
  • Peter Grimm, Ignace Billiet, David Bostwick, Adam P. Dicker, Steven Frank, Jos Immerzeel, Mira Keyes, Patrick Kupelian, W. Robert Lee, Stefan Machtens, Jyoti Mayadev, Brian J. Moran, Gregory Merrick, Jeremy Millar, Mack Roach, Richard Stock, Katsuto Shinohara, Mark Scholz, Ed Weber, Anthony Zietman, Michael Zelefsky, Jason Wong, Stacy Wentworth, Robyn Vera, and Stephen Langley, “Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group,” Bju International, vol. 109, pp. 22–29, 2012. View at PublisherView at Google Scholar
  • Marisa A. Kollmeier, and Michael J. Zelefsky, “How to select the optimal therapy for early-stage prostate cancer,” Critical Reviews in Oncology/Hematology, vol. 84, pp. e6–e15, 2012. View at PublisherView at Google Scholar
  • J. Georgakopoulos, A. Zygogianni, G. Papadopoulos, N. Papandreou, J. Kouvaris, V. Armonis, N. Kelekis, and V. Kouloulias, “Permanent implantation as brachytherapy technique for prostate carcinoma-review of clinical trials and guidelines,” Reviews on Recent Clinical Trials, vol. 7, no. 3, pp. 173–180, 2012. View at PublisherView at Google Scholar
  • Peter Grimmpp. 719–738, 2013. View at PublisherView at Google Scholar
  • Jacek Fijuth, “Surgery for locally advanced prostatic cancer - Is it justifi ed?,” Nowotwory, vol. 63, no. 5, pp. 419–422, 2013. View at PublisherView at Google Scholar
  • Juanita Crook, “Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer,” Brachytherapy, 2014. View at PublisherView at Google Scholar
  • Nicholas A. Serrano, Huong T. Pham, Sreeram Narayanan, and Kas R. Badiozamani, “Permanent prostate brachytherapy using high V150,” Practical Radiation Oncology, 2014. View at PublisherView at Google Scholar
  • Tobin J. Strom, Sean Z. Hutchinson, Kushagra Shrinath, Alex A. Cruz, Nicholas B. Figura, Kevin Nethers, Matthew C. Biagioli, Daniel C. Fernandez, Randy V. Heysek, and Richard B. Wilder, “External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer,” International Braz J Urol, vol. 40, no. 4, pp. 474–483, 2014. View at PublisherView at Google Scholar
  • Jonas Schiffmann, Hans Lesmana, Pierre Tennstedt, Burkhard Beyer, Katharina Boehm, Volker Platz, Derya Tilki, Georg Salomon, Cordula Petersen, Andreas Krüll, Markus Graefen, and Rudolf Schwarz, “Additional androgen deprivation makes the difference,” Strahlentherapie und Onkologie, 2014. View at PublisherView at Google Scholar
  • Tobin J. Strom, Richard B. Wilder, Sean Z. Hutchinson, Kushagra Shrinath, Alex A. Cruz, Nicholas B. Figura, Kevin Nethers, Matthew C. Biagioli, Daniel C. Fernandez, and Randy V. Heysek, “External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer,” International Braz J Urol, vol. 40, no. 4, pp. 493–498, 2014. View at PublisherView at Google Scholar
  • B. Miñana, A. Rodríguez-Antolín, F. Gómez-Veiga, C. Hernández, J.F. Suárez, J.M. Fernández-Gómez, M. Unda, J. Burgos, A. Alcaraz, P. Rodríguez, C. Moreno, E. Pedrosa, and J.M. Cózar, “Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP,” Actas Urológicas Españolas, 2015. View at PublisherView at Google Scholar
  • Robert J. Gillies, Alan Pollack, Mandeep Takhar, Yohann Tschudi, Gabriel Solórzano, Nicholas Erho, Sanoj Punnen, Radka Stoyanova, John C. Ford, Yoganand Balagurunathan, and Elai Davicioni, “Prostate cancer radiomics and the promise of radiogenomics,” Translational Cancer Research, vol. 5, no. 4, pp. 432–447, 2016. View at PublisherView at Google Scholar
  • Peter F. Orio, Paul L. Nguyen, Ivan Buzurovic, Daniel W. Cail, and Yu-Wei Chen, “The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness,” Brachytherapy, 2016. View at PublisherView at Google Scholar
  • B. Miñana, A. Rodríguez-Antolín, F. Gómez-Veiga, C. Hernández, J.F. Suárez, J.M. Fernández-Gómez, M. Unda, J. Burgos, A. Alcaraz, P. Rodríguez, C. Moreno, E. Pedrosa, and J.M. Cózar, “Treatment trends for clinically localized prostate cancer. National population analysis: GESCAP group,” Actas Urológicas Españolas (English Edition), 2016. View at PublisherView at Google Scholar
  • Daniel E. Spratt, Payal D. Soni, Patrick W. McLaughlin, Gregory S. Merrick, Richard G. Stock, John C. Blasko, and Michael J. Zelefsky, “The American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer,” Brachytherapy, 2016. View at PublisherView at Google Scholar
  • Nestor Andres Parra, Alan Pollack, Felix M. Chinea, Matthew C. Abramowitz, Brian Marples, Felipe Munera, Rosa Castillo, Oleksandr N. Kryvenko, Sanoj Punnen, and Radka Stoyanova, “Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness,” Frontiers in Oncology, vol. 7, 2017. View at PublisherView at Google Scholar
  • M. Keyes, G. Merrick, S.J. Frank, P. Grimm, and M.J. Zelefsky, “American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review,” Brachytherapy, 2017. View at PublisherView at Google Scholar
  • Atsushi Takamoto, Ryuta Tanimoto, Kensuke Bekku, Motoo Araki, Takuya Sadahira, Koichiro Wada, Shin Ebara, Norihisa Katayama, Hiroyuki Yanai, and Yasutomo Nasu, “Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer,” International Journal of Urology, 2018. View at PublisherView at Google Scholar